Pierre Charneau

Last updated

Pierre Charneau is a French virologist, inventor, and head of the Molecular Virology and Vaccinology Unit (VMV) at the Pasteur Institute and an acknowledged specialist in HIV, lentiviral gene transfer vectors, and their medical applications. His discovery of the central DNA-flap structure [1] in the HIV genome, and its role in viral entry into the nucleus of the infected cell, grounded the optimization of lentiviral vectors and allowed for more than 20 years of development in gene therapy and vaccines based on this gene delivery technology. Charneau has published more than 100 research articles and holds 25 patents in the field of HIV and lentiviral vectors.

Contents

Education

Charneau studied at the Pierre and Marie Curie University (UPMC) in Paris from which he holds a research doctorate in Molecular and Cellular Biology (1995). [2] After a short time in undergraduate research at the Curie Institute, he pursued his Ph.D. thesis in Luc Montagnier’s Viral Oncology Lab at the Pasteur Institute [3] [4] on reverse transcription, nuclear import, and mitosis-independent integration of HIV genome.

Career and research

Charneau's research led to the discovery and characterization of the central DNA flap structure within the HIV genome and its key function in nuclear import of the lentivirus/HIV genome in non-dividing cells. [5] This discovery enabled the development of lentiviral vectors that can infect non-dividing cells, [6] contrary to other types of retroviral gene transfer vectors, which can only target dividing cells. Since 2000, Charneau has led his own research group at the Pasteur Institute focusing on molecular virology and vectorology. [7] His research has specialized in lentiviral vectors medicinal applications and his publications and patents [8] have led to extensive developments in gene therapy, as well as prophylactic and therapeutic vaccinations in infectious diseases and oncology.

Charneau's development of lentiviral vectors are used in many therapeutic approaches such as those carried out by bluebird bio, [9] [10] CAR-T [11] ), Novartis [12] (CAR-T [13] ), Kite [14] (TCR), Immune Design [15] (Cancer vaccines) and TheraVectys. [16] [17] [18]

Awards and honors

See also

Related Research Articles

<span class="mw-page-title-main">Gene therapy</span> Medical field

Gene therapy is a medical technology that aims to produce a therapeutic effect through the manipulation of gene expression or through altering the biological properties of living cells.

<span class="mw-page-title-main">Retrovirus</span> Family of viruses

A retrovirus is a type of virus that inserts a DNA copy of its RNA genome into the DNA of a host cell that it invades, thus changing the genome of that cell. After invading a host cell's cytoplasm, the virus uses its own reverse transcriptase enzyme to produce DNA from its RNA genome, the reverse of the usual pattern, thus retro (backwards). The new DNA is then incorporated into the host cell genome by an integrase enzyme, at which point the retroviral DNA is referred to as a provirus. The host cell then treats the viral DNA as part of its own genome, transcribing and translating the viral genes along with the cell's own genes, producing the proteins required to assemble new copies of the virus. Many retroviruses cause serious diseases in humans, other mammals, and birds.

<i>Adenoviridae</i> Family of viruses

Adenoviruses are medium-sized, nonenveloped viruses with an icosahedral nucleocapsid containing a double-stranded DNA genome. Their name derives from their initial isolation from human adenoids in 1953.

<span class="mw-page-title-main">Luc Montagnier</span> French virologist and Nobel laureate (1932–2022)

Luc Montagnier was a French virologist and joint recipient, with Françoise Barré-Sinoussi and Harald zur Hausen, of the 2008 Nobel Prize in Physiology or Medicine for his discovery of the human immunodeficiency virus (HIV). He worked as a researcher at the Pasteur Institute in Paris and as a full-time professor at Shanghai Jiao Tong University in China.

<span class="mw-page-title-main">Adeno-associated virus</span> Species of virus

Adeno-associated viruses (AAV) are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae. They are small replication-defective, nonenveloped viruses and have linear single-stranded DNA (ssDNA) genome of approximately 4.8 kilobases (kb).

Lentivirus is a genus of retroviruses that cause chronic and deadly diseases characterized by long incubation periods, in humans and other mammalian species. The genus includes the human immunodeficiency virus (HIV), which causes AIDS. Lentiviruses are distributed worldwide, and are known to be hosted in apes, cows, goats, horses, cats, and sheep as well as several other mammals.

<i>Gammaretrovirus</i> Genus of viruses

Gammaretrovirus is a genus in the Retroviridae family. Example species are the murine leukemia virus and the feline leukemia virus. They cause various sarcomas, leukemias and immune deficiencies in mammals, reptiles and birds.

The genome and proteins of HIV (human immunodeficiency virus) have been the subject of extensive research since the discovery of the virus in 1983. "In the search for the causative agent, it was initially believed that the virus was a form of the Human T-cell leukemia virus (HTLV), which was known at the time to affect the human immune system and cause certain leukemias. However, researchers at the Pasteur Institute in Paris isolated a previously unknown and genetically distinct retrovirus in patients with AIDS which was later named HIV." Each virion comprises a viral envelope and associated matrix enclosing a capsid, which itself encloses two copies of the single-stranded RNA genome and several enzymes. The discovery of the virus itself occurred two years following the report of the first major cases of AIDS-associated illnesses.

Virus latency is the ability of a pathogenic virus to lie dormant within a cell, denoted as the lysogenic part of the viral life cycle. A latent viral infection is a type of persistent viral infection which is distinguished from a chronic viral infection. Latency is the phase in certain viruses' life cycles in which, after initial infection, proliferation of virus particles ceases. However, the viral genome is not eradicated. The virus can reactivate and begin producing large amounts of viral progeny without the host becoming reinfected by new outside virus, and stays within the host indefinitely.

<span class="mw-page-title-main">Viral vector</span> Biotechnology to deliver genetic material into a cell

Viral vectors are tools commonly used by molecular biologists to deliver genetic material into cells. This process can be performed inside a living organism or in cell culture. Viruses have evolved specialized molecular mechanisms to efficiently transport their genomes inside the cells they infect. Delivery of genes or other genetic material by a vector is termed transduction and the infected cells are described as transduced. Molecular biologists first harnessed this machinery in the 1970s. Paul Berg used a modified SV40 virus containing DNA from the bacteriophage λ to infect monkey kidney cell maintained in culture.

<span class="mw-page-title-main">Robert Gallo</span> American biomedical researcher

Robert Charles Gallo is an American biomedical researcher. He is best known for his role in establishing the human immunodeficiency virus (HIV) as the infectious agent responsible for acquired immune deficiency syndrome (AIDS) and in the development of the HIV blood test, and he has been a major contributor to subsequent HIV research.

<span class="mw-page-title-main">Rev (HIV)</span> HIV-1 regulating protein

Rev is a transactivating protein that is essential to the regulation of HIV-1 protein expression. A nuclear localization signal is encoded in the rev gene, which allows the Rev protein to be localized to the nucleus, where it is involved in the export of unspliced and incompletely spliced mRNAs. In the absence of Rev, mRNAs of the HIV-1 late (structural) genes are retained in the nucleus, preventing their translation.

Gene therapy using lentiviral vectors was being explored in early stage trials as of 2009.

<span class="mw-page-title-main">Oxford Biomedica</span> BioTech Company

Oxford Biomedica is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange.

<span class="mw-page-title-main">André Choulika</span>

André Choulika is a biotechnologist, the inventor of nuclease-based genome editing and a pioneer in the analysis and use of meganucleases to modify complex genomes.

<span class="mw-page-title-main">Lentiviral vector in gene therapy</span>

Lentiviral vectors in gene therapy is a method by which genes can be inserted, modified, or deleted in organisms using lentiviruses.

DNA-directed RNA interference (ddRNAi) is a gene-silencing technique that utilizes DNA constructs to activate an animal cell's endogenous RNA interference (RNAi) pathways. DNA constructs are designed to express self-complementary double-stranded RNAs, typically short-hairpin RNAs, that bring about the silencing of a target gene or genes once processed. Any RNA, including endogenous messenger RNA (mRNAs) or viral RNAs, can be silenced by designing constructs to express double-stranded RNA complementary to the desired mRNA target.

Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia. It was developed by Bluebird Bio and was given breakthrough therapy designation by the US Food and Drug Administration in February 2015.

Since antiretroviral therapy requires a lifelong treatment regimen, research to find more permanent cures for HIV infection is currently underway. It is possible to synthesize zinc finger nucleotides with zinc finger components that selectively bind to specific portions of DNA. Conceptually, targeting and editing could focus on host cellular co-receptors for HIV or on proviral HIV DNA.

<span class="mw-page-title-main">Didier Trono</span> Swiss virologist

Didier Trono is a Swiss virologist and a professor at the École Polytechnique Fédérale de Lausanne (EPFL). He is known for his research on virus-host interactions and the development of lentiviral vectors for gene therapy.

References

  1. Charneau, Pierre; Montagnier, Luc; Nerhbass, Ulf; Guetard, Denise; Petit, Caroline; Zennou, VÃronique (2000-04-14). "HIV-1 Genome Nuclear Import Is Mediated by a Central DNA Flap". Cell. 101 (2): 173–185. doi: 10.1016/S0092-8674(00)80828-4 . ISSN   0092-8674. PMID   10786833. S2CID   9606648.
  2. https://fr.linkedin.com/in/pierre-charneau-49829749 [ self-published source ]
  3. "Le virus du sida pour soigner le cancer". ladepeche.fr (in French). Retrieved 2019-02-04.
  4. "Quand le virus transporte des gènes-médicaments". Sciences et Avenir (in French). Retrieved 2019-02-04.
  5. Charneau, Pierre; Montagnier, Luc; Nerhbass, Ulf; Guetard, Denise; Petit, Caroline; Zennou, Véronique (2000-04-14). "HIV-1 Genome Nuclear Import Is Mediated by a Central DNA Flap". Cell. 101 (2): 173–185. doi: 10.1016/S0092-8674(00)80828-4 . ISSN   0092-8674. PMID   10786833. S2CID   9606648.
  6. Charneau, Pierre; Dubart-Kupperschmitt, Anne; Coulombel, Laure; Vainchenker, William; Titeux, Monique; Zennou, Véronique; Pflumio, Françoise; Sirven, Aude (2000-12-15). "The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells". Blood. 96 (13): 4103–4110. doi:10.1182/blood.V96.13.4103. ISSN   0006-4971. PMID   11110680.
  7. Pasteur, research pasteur fr-Institut. "Molecular Virology and Vaccinology • Research". Research. Retrieved 2019-01-30.
  8. "Pierre Charneau Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved 2019-02-04.
  9. "S-1". www.sec.gov. Retrieved 2019-01-30.
  10. "bluebird bio Presents New Data for LentiGlobin Gene Therapy in Transfusion Dependent β-Thalassemia at 60th Annual Meeting of the American Society of Hematology". www.businesswire.com. 2018-12-04. Retrieved 2019-01-30.
  11. "SEC Filing | bluebird bio, Inc". investor.bluebirdbio.com. Retrieved 2019-01-30.
  12. "bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies". www.businesswire.com. 2017-05-02. Retrieved 2019-01-30.
  13. "Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice". Novartis. Retrieved 2019-01-30.
  14. "Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers". bluebird bio, Inc. Retrieved 2019-01-30.
  15. "Immune Design enters settlement, license pacts with TheraVectys IMDZ - The Fly". thefly.com. Retrieved 2019-01-30.
  16. "Theravectys' HIV Cure on the Road to Success". Labiotech.eu. 2015-07-20. Retrieved 2019-01-30.
  17. "Immunotherapy reaches Breakthrough in eliminating HIV". Labiotech.eu. 2016-06-13. Retrieved 2019-01-30.
  18. "The 10 Most Innovative HIV Treatments to Defeat AIDS". Labiotech.eu. 2017-09-13. Retrieved 2019-01-30.
  19. "Lauréats 2004 des Prix de l'Académie des sciences" (PDF). 2004. Retrieved 2019-04-19.
  20. "2009 Awards by the Fondation pour la Recherche Médicale" (PDF).